Second-quarter catalysts for the smaller players
Key catalysts approach for Orphazyme, Gemini and Immutep.
Orphazyme's recent setback with arimoclomol in a muscle-wasting disease puts a damper on upcoming data in amyotrophic lateral sclerosis (ALS). Meanwhile, Gemini's new approach to geographic atrophy will yield data, and Immutep hopes to rebound with results on its Lag3 project eftilagimod alpha.
The news last week that Orphazyme’s lead project arimoclomol had failed in a phase 2/3 study in inclusion body myositis (IBM) caused shares to plummet 30%. The stumble, not the first for arimoclomol, leaves questions marks over the company’s next data readout in ALS, due in the second quarter. The project is one of the most advanced in the ALS pipeline following the failure of Brainstorm's NurOwn last year.
The 245-patient phase 3 study is testing 400mg of oral arimoclomol three times daily, versus placebo, for 18 months. The primary endpoint is the combined assessment of function and survival, which ranks patients’ clinical outcomes based on survival time and change in the ALS Functional Rating Scale-Revised (ALSFRS-R).
The same dosing was used in the failed IBM study, but Orphazyme was keen to point out the differences between the two diseases, noting IBM is a progressive muscle-wasting disorder while ALS is a neurodegenerative disease.
But arimoclomol, which is thought to work by stimulating heat-shock proteins, missed the endpoints of a registrational study in Niemann-Pick disease type C, a rare inherited condition that causes progressive neurodegeneration and death. Nonetheless the FDA has accepted a filing for the project, perhaps swayed by signs of disease stabilisation or a lack of options for NPC; arimoclomol has a Pdufa date here of June 17.
Gemini's complement approach
Geographic atrophy, an advanced form of age-related macular degeneration, has proven another difficult disease to crack. Gemini Therapeutics, which went public via the Spac route in February, will soon find out if it has a chance here: phase 2 data on its lead project, GEM103, are due this quarter.
Like others in the space, Gemini is hitting the complement cascade. However, GEM103 works differently to other projects in development, being a recombinant form of complement factor H (CFH), a modulator of the alternative complement pathway.
The single-arm phase 2a Regatta study is testing repeat intravitreal injections of GEM103 in 60 patients with dry AMD and loss of function CFH variants. This population makes up around 40% of geographic atrophy patients.
The main purpose of the trial is to inform the design of an upcoming sham-controlled phase 2b study, but investors will be looking for clues about whether the group’s novel approach works.
Stifel analysts want to see three things: clean safety, with a close eye on choroidal neovascularisations; consistent and durable biomarker reductions; and possibly favourable efficacy – the study is assessing lesion growth and best corrected visual acuity. Still, any data here could be difficult to interpret given the lack of a placebo arm.
Choroidal neovascularisations are new, damaging blood vessels that are seen in wet AMD. They are under the spotlight after being observed in the phase 2 Filly study of another geographic atrophy contender, Apellis’s C3 inhibitor pegcetacoplan. That group’s pivotal trials, Derby and Oaks, are set to yield data in the third quarter.
Lag3's potential in immuno-oncology was crystallised last month when Bristol Myers Squibb’s Relativity-047 study showed the anti-Lag3 MAb relatilimab to boost the activity of Opdivo in front-line melanoma. One of the beneficiaries was Australia’s Immutep, a Lag3-focused biotech whose stock spiked 30%.
But the shares have fallen back as two 2021 catalysts near for Immutep’s own eftilagimod alpha, a soluble Lag3 dimer. These comprise a second overall survival readout from the AIPAC paclitaxel-combo breast cancer trial, and data from TACTI-002, a solid tumour study in combination with Merck & Co’s Keytruda.
Immutep will have to hope that the data improve as AIPAC matures: its first OS assessment found a 17% reduction in risk of death versus paclitaxel alone, but this was not significant, with a p value of 0.140.
TACTI-002 comprises first-line and PD-(L)1-refractory NSCLC, and head and neck cancer, where so far the combo has yielded remission rates of 39%, 4% and 43% respectively. A major caveat is that TACTI-002 is uncontrolled, so any comparison will be against Keytruda monotherapy on a cross-trial basis.
Eftilagimod, one of Immutep’s four Lag3 approaches, works on the basis that Lag3 itself can activate antigen-presenting cells. Leramilimab (IMP701/LAG525) is an antagonist analogous to relatlimab and licensed to Novartis; the agonist MAb IMP761, and the depleting MAb IMP731 (licensed to Glaxosmithkline as GSK2831781) are for autoimmune diseases.
The table below contains a fuller list of upcoming catalysts with consensus forecasts from Evaluate Pharma. Evaluate Vantage has previously looked at clinical data expected for big pharma and biotech companies.
|Q2 clinical catalysts (excludes Covid-19 data)|
|Product||Company||Therapy area||Q2 clinical catalyst||2026e indication sales ($m)||Note/Vantage coverage|
|ACI-24||AC Immune||Alzheimer's disease||Ph2 18-month data||1,606*||Focus on safety & tolerability|
|Anavex||Rett Syndrome||Ph2 Avatar, adults (Aus); ph2/3 Excellence, paediatric||568||Ph2 US trial met primary and secondary endpoints|
|Vamorolone||Santhera||Duchenne muscular dystrophy||Topline 6mo data Ph2b Vision-DMD pivotal trial||450||Vam vs prednisone vs placebo|
|Eftilagimod alpha||Immutep||Breast cancer/ NSCLC/head & neck||Ph2b AIPAC OS data, further data from TACTI-002 (+ Keytruda)||440||See text|
|SNDX-5613||Syndax||Relapsed/refractory leukaemias||Ph1 Augment-101||407||Oral menin inhibitor, rival to Kura's KO-539 (Ash 2020 – Kura looks to take on Syndax)|
|SB206||Novan||Molluscum contagiosum||Ph3 B-Simple4||358||Topical antiviral|
|Losmapimod||Fulcrum||Facioscapulohumeral muscular dystrophy||ReDUX4 data in 80 patients||295||At interim look biopsy data did not show a separation from placebo (Fulcrum’s biopsy conundrum)|
|Plinabulin||Beyondspring||NSCLC||Final data from Dublin-3||284||+ docetaxel in 2/3L NSCLC|
|Lenabasum||Corbus||Dermatomyositis||Ph3 Determine||189||Failed in systemic sclerosis and cystic fibrosis|
|ADP-A2M4||Adaptimmune||Synovial sarcoma||Ph2 Spearhead-1 preliminary data at Asco||149||Mage A4 TCR therapy, prior safety issues (More deaths raise further questions about Adaptimmune)|
|Reproxalap ophthalmic solution||Aldeyra||Allergic conjunctivitis||Ph3 Invigorate top line||106||Dry eye data not expected until H2|
|Inflarx||ANCA-associated vasculitis||Ph2 Ixplore final due mid year||90||
Project failed in hidradenitis suppurativa (Inflarx pushes past the red flags to claim a win)
|STRO-002||Sutro||Ovarian cancer||Ph1 updated dose-escalation data||88||Anti-FRα MAb-drug conjugate, promising early data but issues with neutropenia (Sutro bucks the folate trend)|
|Oral Korsuva||Cara||Pruritus in atopic dermatitis patients||Ph2 Kare||30||Oral missed secondary endpoint in CKD, IV has Aug Pdufa in haemodialysis pts with pruritus (Big placebo response rattles Cara ahead of pivotal tests)|
|GEM103||Gemini||Dry AMD patients with CFH loss-of-function gene variants||Ph2 Regatta||-||See text|
|* $1,496m assigned to undisclosed partner sales. Sources: EvaluatePharma, company releases, analyst notes & clinicaltrials.gov.|